First vaccine in the world developed against grass pollen allergy

Around 400 million people world-wide suffer in some form or other from a grass pollen allergy (rhinitis) – with the usual symptoms such as a runny nose, cough and severe breathing problems. Medical researchers have now shown in a Phase II-b study with 180 patients in 11 European centers, that four injections of the synthetically manufactured vaccine BM32 in the first year and a top-up in the second year of treatment relieve the sufferers’ symptoms by at least 25%.